Navigation Links
Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women
Date:12/18/2007

ir recurrence risk, and is set to improve the outcomes of patients worldwide," commented Professor Anthony Howell, Christie Hospital, UK.

ATAC 100-month results summary:

-- After a median follow-up of over 8 years (100 months), compared with

tamoxifen, anastrozole significantly:(1),(2)

-- reduces the risk of all recurrences by 24% (HR 0.76 [0.67-0.87];

p=0.0001)

-- improves disease free survival by 15% (HR 0.85 [0.76-0.94]; p=0.003)

-- reduces the risk of distant metastases (recurrence elsewhere in the

body) by 16% (HR 0.84 [0.72-0.97]; p=0.022)

-- reduces the incidence of contralateral breast cancer (cancer in the

opposite breast) by 40% (OR 0.60 [0.42-0.85]; p=0.004)

-- Prescribing anastrozole from the start means fewer patients have to

be told the devastating news that their breast cancer has

recurred.(1),(2)

Notes to Editors

For more information, to view a presentation of the ATAC 100 data by Professor John Forbes or to download the ATAC 100 publication in The Lancet Oncology, please visit http://www.ATAC100.com

The study will be published early online (00.01 GMT Saturday 15 December) and in the January edition of The Lancet Oncology.

* ATAC: Arimidex, Tamoxifen, Alone or in Combination

** Physicians: medical oncologists, gynaecologists and breast cancer

surgeons

Patients: postmenopausal women diagnosed with early breast cancer in

the past five years and who had undergone breast cancer surgery

Broadcast-quality video

For broadcast-standard video supporting this press release, please visit http://www.thenewsmarket.com/astrazeneca. If you are a first-time user, please take a moment to register. In case you have any questions, please email

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Tapestry Reports Second Quarter 2007 Results
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Spherix Incorporated (NASDAQ: SPEX ... diabetes, metabolic syndrome and atherosclerosis, and providers of technical ... pharmaceutical companies, is issuing the following reminder that Spherix ... business update and answer questions today at 12:00 noon ...
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ) ... develops new uses for previously approved drugs and new ... PTO notification of the allowance of two important U.S. ... class of compounds that combine elements of diketopiperazines (same ...
Cached Medicine Technology:Spherix Issues Reminder of Business Update Conference Call Set for Today at Noon Eastern Time 2Spherix Issues Reminder of Business Update Conference Call Set for Today at Noon Eastern Time 3Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases 2
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... Lipitor bellwether trial has been scheduled in July of ... The Lipitor lawsuits are in the discovery process ... Judge Richard M. Gergel is presiding over the multidistrict ... were filed on behalf of individuals who allege that ...
(Date:7/13/2014)... ECS is being founded by Seattle ... a special needs child, I have become keenly aware ... contemporary special education resources and evidence-based instruction. Emerald City ... families in the Seattle metro area that are looking ... We welcome the opportunity to serve our community and ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According to ... this is a comprehensive program that teaches people how ... peripheral neuropathy without medications. This program also provides ... symptoms of peripheral neuropathy , including numbness, prickling, burning, ... its review that this home treatment program can help ...
(Date:7/12/2014)... 13, 2014 According to the new ... Systems, Airborne Systems, and Naval Systems) - Global Forecasts ... Security and Surveillance Radar market are estimated to be ... a CAGR of 5.97% to reach $8.61 billion by ... with 47 figures spread through 161 pages and in-depth ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4
... likely to display abnormal social behaviour and make poor ... according to research in the January issue of the ... of studies have already associated pathological gambling with Parkinson,s, ... associated mainly with dopamine replacement therapy. Researchers ...
... and tendons work together to provide the perfect balance ... Institute scientists show that this partnership begins in the ... study, published in a recent issue of Developmental ... and bones that drives the development of a strong ...
... cholesterol-lowering effect, study suggests , THURSDAY, Jan. 14 (HealthDay ... effect of statin drug therapy on the risk of ... , Much of the benefit from statins such as ... lowering of blood levels of "bad" LDL cholesterol, the ...
... EUGENE, Ore. , Jan. 14 The Tech-Aid ... unprecedented work, has released another interactive CD-ROM for people with ... Disabilities. , With AIDS being the fifth leading cause of ... United States , this interactive computer program helps women with ...
... ... of the industry’s leading hospitality installation companies. JK Logistical Operations was founded by ... operations offices in Dallas and Denver. , ... Chicago, IL (PRWEB) January 14, 2010 -- JK Logistical Operations ...
... ... allows increased coatings development ,capacity., , ... Horsham, PA (PRWEB) January 14, 2010 -- Biocoat, Inc., maker of ... that allows increased coatings development capacity. Biocoat and DipTech Systems, Inc. cooperated ...
Cached Medicine News:Health News:Parkinson's patients who are pathological gamblers also display abnormal social behavior 2Health News:Weizmann Institute scientists reveal how tendons shape developing bones 2Health News:More Evidence That Statins Cut Stroke Risk 2Health News:More Evidence That Statins Cut Stroke Risk 3Health News:The Tech-Aid Institute Releases HIV/AIDS Prevention Software for Women with Intellectual Disabilities 2Health News:JK Logistical Operations Acquires JDL Installation Logistics 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: